UNSPSC 51361940: Secobarbital sodium

This classification denotes a barbiturate with the molecular formula C12H17N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XBP604F6UM, chemically known as 2,4,6 (1h,3h,5h)-pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)-, monosodium salt but more generally known as secobarbital sodium, which bears US NIH Compound Identifier 5193. European Medicines Agency schedules Secobarbital sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04344MIG.

Most nations, for tariff and trade purposes, schedule secobarbital sodium under HS 29335300 and SITC 51576. As of Q4 2014, SECOBARBITAL SODIUM remains US FDA's Preferred Term for this commodity. Secobarbital sodium bears US NLM identifiers UMLS ID C0304359 and NCI Concept Code C66530. SMILES: CCCC(C)C1(C(=O)NC(=O)[N-]C1=O)CC=C.[NA+].

UNSPSC 51361940 Secobarbital sodium is a Commodity code that in practice covers the procurement of pharmaceutical products by state and local health agencies, though recent solicitations under this code show limited direct activity tied to the specific barbiturate named. The three most recent opportunities posted under or near this code reflect a broader state and local pharmaceutical procurement landscape focused on generic multi-source drugs, opioid-response medications like naloxone, and over-the-counter products distributed through established wholesaler networks and cooperative purchasing vehicles. State and local buyers under this code family include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida, and the Texas Health and Human Services Commission represent issuing bodies active in this space, as does the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which operates a cooperative agreement serving multiple state and local participants across the upper Midwest and Pacific Northwest.

Recent activity is concentrated in Florida, Texas, and Minnesota. Seminole County released IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries through July 26, 2023 response deadline; the Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs; and MMCAP issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and contract effectiveness targeted for July 1, 2026. The MMCAP vehicle requires vendors to maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and submit pricing in multiple formats; evaluation weights 75 percent price competitiveness against 25 percent combined administrative, EDI, and compliance criteria. Opportunities under this code do not typically feature explicit set-aside designations for disadvantaged enterprises.